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Background: Natriuretic peptides are considered as reliable indicators of left-heart
failure (HF) and are useful for differential diagnosis of dyspnoea.
Aim: We evaluated the clinical significance of N-terminal pro-brain natriuretic peptide
(NT-proBNP) in patients with chronic hypercapnic respiratory failure (CHRF).
Methods: In 60 patients with CHRF, plasma concentrations of NT-proBNP were assessed at
baseline and after treatment including non-invasive ventilation (NIV). The relationship
of NT-proBNP to disease severity and its predictive value for survival were evaluated up to
4 years.
Results: NT-proBNP levels were markedly elevated in patients with CHRF (n ¼ 60;
geometric mean (SD) 546.4 (4.9) pg/mL; po0.001) compared to healthy controls (n ¼ 182;
49.0 (2.2) pg/mL). After excluding patients with concomitant HF or renal impairment,
levels were still increased (n ¼ 43; 393.2 (3.8) pg/mL; po0.001). According to multi-
variate regression, hypoxia and exacerbation independently determined NT-proBNP
levels (po0.05 each). After initiation of NIV, blood gases and lung function improved andElsevier Ltd. All rights reserved.
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S. Budweiser et al.2004NT-proBNP decreased (31.3 (0.3)%; po0.001). During 22.5 (2.2) months follow-up,
NT-proBNP was not significantly associated with survival in the total population, however,
the subgroup of patients with levels 4722 pg/mL (67th percentile) and no adherence to
NIV displayed poor prognosis (hazard ratio ¼ 0.21; 95%-CI ¼ 0.022–0.580; p ¼ 0.0091).
Conclusions: NT-proBNP was highly elevated in patients with CHRF and correlated with
the degree of respiratory impairment and exacerbation. Correspondingly, treatment
including NIV led to reduction of NT-proBNP. These data indicate a potential role of NT-
proBNP in assessing disease severity, treatment efficacy and prognosis in CHRF.
& 2007 Elsevier Ltd. All rights reserved.Introduction
B-type natriuretic peptide (BNP) and N-terminal pro BNP
(NT-proBNP) are indicators and prognostic factors for left-
heart failure (HF) and valuable markers for risk stratification
in acute coronary syndrome.1,2 Moreover, natriuretic pep-
tides have been demonstrated to be useful for the
differential diagnosis of acute dyspnoea in the emer-
gency department3 and the identification of acute HF in
particular.4–6
Elevated levels of natriuretic peptides have also been
reported in critically ill patients and a multitude of
conditions other than primary cardiac diseases.7 Recently,
increased BNP values have been found to be correlated with
pulmonary hypertension in chronic lung diseases of different
aetiologies and to serve as a risk factor for mortality.8
Pulmonary hypertension is common and a leading cause of
death especially in patients with chronic respiratory failure.
The reduction of mortality by long-term oxygen therapy
(LTOT) in chronic hypoxia is presumably due to a reduction
of pulmonary artery pressure,9 associated with a decrease in
BNP concentrations.10 However, while the role of hypoxemia
for the development of pulmonary hypertension is consi-
dered well established, that of hypercapnia is less clear.
It has been demonstrated in patients with chronic
hypercapnic respiratory failure (CHRF), that the use of
non-invasive ventilation (NIV) and the consecutive reduction
in hypercapnia was associated with a decrease of pulmonary
artery pressure.11,12 This also suggests a role for hypercap-
nia in the development of pulmonary hypertension. Thus,
elevated concentrations of natriuretic peptides might be
expected especially in patients with CHRF.
Based on these considerations, the present prospective
controlled trial aimed to assess levels of NT-proBNP and
their association with functional indices in patients with
CHRF. Furthermore, we evaluated the predictive value of
baseline NT-proBNP levels for long-term survival and their
changes after treatment including NIV.Methods
Patients and selection criteria
We prospectively enrolled patients with CHRF who were
admitted to the Hospital Donaustauf, University of Regens-
burg, for initiation of NIV between February 2002 andOctober 2005. Following guidelines, the decision for NIV was
based on symptoms such as dyspnoea, fatigue or morning
headache, arterial carbon dioxide tension (PaCO2445mmHg),
and pulmonary dysfunction.13 Underlying disorders com-
prised chronic obstructive pulmonary disease (COPD), chest
wall diseases (CWD), obesity-hypoventilation syndrome (OHS)
and neuromuscular disorders (NMD).
The diagnosis of COPD was based on guidelines of the
American Thoracic Society (ATS).14 Exacerbations were
defined via the worsening of respiratory symptoms, elevated
inflammation markers and treatment by antibiotics and/or
oral steroids. Patients with the diagnosis of a malignancy
within 5 years prior to study entry, or patients who had
been switched from tracheostomy to NIV were not included.
The control group consisted of 182 asymptomatic subjects
in whom cardiac and renal diseases were excluded by
echocardiography and serum creatinine measurements.15
The study was approved by the local Ethics Committee and
patients gave their informed consent.
Measurements at baseline
Upon admission and prior to initiation of NIV, blood gases
were measured (Rapidlab; Bayer Inc; East Walpole, MA, USA)
in samples taken from the hyperaemic earlobe during
daytime at rest and spontaneous breathing of room air or
patients’ usual oxygen flow. Spirometry and bodyplethysmo-
graphy followed ATS guidelines using ERS reference values.16
An electrocardiogram was performed to detect sinus rhythm
or atrial fibrillation. HF (systolic ejection fraction o60%)
and right ventricular dimensions were assessed by 2D and
M-mode echocardiography, and systolic pulmonary artery
pressure (sPAP) was determined from tricuspid regurgitation
peak velocity.
Biochemical markers
Before initiation of NIV, peripheral venous blood samples
were collected in the morning after patients had been
at least 10min at rest. For the determination of serum
NT-proBNP blood levels, EDTA plasma was immediately
centrifuged and frozen at 80 1C until measurement by a
commercially available radio immunoassay (Elecsys, Roche
Diagnostics, Mannheim, Germany). The assay had a minimal
analytic and functional sensitivity of 5 and 50 pg/mL,
respectively. Serum creatinine, C-reactive protein (CRP),
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60-CT, ABX Inc., Montpellier, France; Dimension Xpand, Dade
Behring Inc., Schwalbach, Germany).
NIV technique and setting
Upon initiation of NIV the ventilator was set in the
spontaneously timed (assist-controlled) mode with low
inspiratory pressure and respiratory frequency. After a
period of adaptation, ventilation parameters were set to
the patient’s comfort to achieve effective passive ventila-
tion. The aim was a reduction in PaCO2 of about 20% during
NIV, based on repeated measurements of blood gases.17
Oxygen was supplemented to maintain a saturation of
X90%.
NIV was applied via nasal, full-face or custom-made masks
in cases of persistent leakage and/or nasal ulceration. If dry
mucosa developed, a humidification system was installed.
Different ventilators were used, mostly Twin Airs, Smart
Airs (both Airox Inc., Pau, France) or BIPAP Synchrony STs
(Respironics Inc., Murrysville, PA, USA).
Out of the 60 patients, 12 patients (20%; nine patients
with COPD and three patients with restrictive diseases)
refused NIV for long-term use and were discharged without
NIV, whereas in the majority (n ¼ 48; 80%) home NIV was
prescribed. Upon discharge, these patients were ventilated
with a expiratory airway pressure of 4.7 (1.2)mbar, an
inspiratory airway pressure of 19.6 (1.3)mbar and a
respiratory frequency of 16.8 (1.2) /min.
Follow-up
Patients were re-admitted to the hospital about 6 months
after initiation of NIV for re-evaluation. Adherence to NIV
therapy was assessed via counter readings of the ventilator
after 3 months. Lung function, blood gases and laboratory
parameters including NT-proBNP serum levels were re-
assessed as upon inclusion. For survival analysis, patients
were followed until death or until the end of the study
period in February 2006, but for at least 6 months after
discharge. Information on mortality was obtained from the
patients’ relatives and/or family doctors.
Data analysis
Results are expressed as arithmetic mean values 7standard
deviations (SD) or geometric mean values and geometric SD,
depending on the data distribution. The geometric SD is
presented as a factor to be multiplied with the geometric
mean. NT-proBNP values were log-transformed for all
analyses. Shapiro-Wilk-tests were performed to test for
normal distribution of either original or transformed values.
Baseline characteristics were compared between groups by
the unpaired t-test for quantitative variables, and by
Fisher’s exact test for binary variables. Changes from
baseline to follow-up were evaluated by the paired t-test.
The associations between NT-proBNP, lung function and
blood gases were assessed by univariate linear regression.
Factors significant in these analyses were fed into a
multivariate regression analysis to identify independent
predictors. Correlations were quantified by Pearson’s linearcorrelation coefficient. The predictive value of NT-proBNP
for all-cause mortality was evaluated by univariate regres-
sion using the log-rank test. A p-value of o0.05 was
considered as statistically significant. The SPSS software
package (V. 10.0, Chicago IL, USA) was used.
Results
Patients’ characteristics at baseline
Among the 60 patients with CHRF, six patients experienced
an exacerbation upon admission. The majority (n ¼ 39;
65.0%) had already been treated with LTOT when included.
In 13 patients, LTOT was initiated in addition to NIV. All
patients showed a dilatated or hypertrophied right ven-
tricle, with a sPAP of 48.5713.5mmHg (n ¼ 28). Baseline
characteristics of patients are shown in Table 1. Patients
who refused NIV from the beginning were not different from
the others regarding NT-proBNP levels, lung function, or
blood gas values, except for BMI which was lower in these
patients (23.376.6 vs. 28.978.8 lkg/m2; po0.05).
NT-pro BNP in CHRF
In patients with CHRF, NT-proBNP levels were markedly
elevated (n ¼ 60; geometric mean (SD) 546.4 (4.9) pg/mL)
compared to healthy controls (n ¼ 182; 49.0 (2.2) pg/mL;
Fig. 1). The same was true, when using for comparison the
level (73.5 pg/mL) that had been adjusted to the character-
istics of the patients’ population according to the results of
multivariate regression analysis performed in the control
group; the significant predictors of proBNP within the
control group were age and haemoglobin (po0.001 each).
NT-proBNP concentrations were not significantly different
between restrictive and obstructive disorders (Table 1).
Similarly, when NT-proBNP concentrations of patients with
COPD (n ¼ 35; 506.2 (4.8) pg/mL) were compared with
those of OHS (n ¼ 3; 2432.8 (2.5) pg/mL), or CWD (n ¼ 19;
529.5 (4.9) pg/mL), or NMD (n ¼ 3; 201.3 (7.3) pg/mL), no
significant differences were detected. After excluding
patients with concomitant HF or impaired renal function
(creatinine 41.0mg/dL), levels were still significantly
increased (n ¼ 43; 393.2 (3.8) pg/mL; po0.001; Fig. 1)
compared to controls.
Association of NT-proBNP with cardiac or pulmonary
parameters
Univariate analyses of markers of non-pulmonary function
indicated a significant correlation of NT-proBNP with left
ventricular dysfunction (n ¼ 60; r ¼ 0.34; p ¼ 0.009) and
creatinine (n ¼ 60; r ¼ 0.27; p ¼ 0.040). In this cohort,
there was no significant association with atrial fibrillation,
age, sex, BMI, or haemoglobin.
When evaluating the correlation between NT-pro BNP
and markers of respiratory function, patients with HF or
impaired renal function were excluded, to circumvent the
dominant effect of these disorders on NT-proBNP levels. In
the 43 remaining patients, NT-proBNP was correlated with
PaO2 (n ¼ 36; r ¼ 0.66; po0.001) and PaCO2 (n ¼ 36;
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Table 1 Baseline characteristics according to the type of the disease (n ¼ 60).
Parameter All patients Obstructive disease Restrictive disease p-valuea
N 60 35 25 –
Age (yrs) 63.0711.1 64.079.7 61.8712.6 0.450
Sex (f/m) 26/34 12/23 14/11 0.059
BMI (kg/m2) 27.878.7 25.677.9 30.178.7 0.018
NT-proBNP (pg/mL)b 546.4 (4.9) 506.2 (4.8) 608.0 (5.1) 0.665
Creatinine (mg/dL) 0.8670.23 0.8570.20 0.8670.28 0.909
Haemoglobin (g/dL) 14.172.3 14.272.6 13.971.9 0.554
Leukocytes (103/mL) 8.473.7 8.874.6 7.872.0 0.209
CRP (mg/dL) 18.9755.7 24.9771.8 10.4714.0 0.258
Left-heart failure (y/n) 9/51 6/29 3/22 0.430
Sinus rhythm (y/n) 56/4 33/2 23/2 0.574
Systemic hypertension (y/n) 23/37 11/24 12/13 0.282
ACE-inhibitor (y/n) 16/44 8/27 8/17 0.556
AT-II-RA (y/n) 7/53 5/30 2/23 0.688
Exacerbation (y/n) 6/54 4/31 2/23 0.488
FEV1 (%pred) 34.5712.7 29.879.3 40.1714.6 0.001
FEV1/VC (%) 59.4720.8 45.0710.1 80.0713.6 o0.001
RV/TLC (%) 69.979.4 74.577.2 62.977.8 o0.001
pH 7.4170.04 7.4070.04 7.4170.04 0.191
PaO2 (mmHg) 60.9713.5 61.7713.9 59.9712.9 0.561
PaCO2 (mmHg) 57.677.2 59.177.3 54.877.3 0.048
BE (mmol/L) 8.674.0 8.273.5 8.774.8 0.472
pHc 7.4170.04 7.4170.04 7.4370.03 0.060
PaO2 (mmHg)
c 49.679.5 48.779.3 51.2710.0 0.377
PaCO2 (mmHg)
c 53.877.1 54.777.8 52.176.4 0.206
BE (mmol/L)c 7.874.0 7.072.6 8.775.2 0.174
sPAP (mmHg)d 48.5713.5 45.4713.2 51.7713.4 0.218
Definition of abbreviations: BMI, body-mass-index; NT-proBNP, N-terminal pro B-type natriuretic peptide; CRP, C-reactive protein;
FEV1, forced expiratory volume in one second; VC, vital capacity; RV, residual volume; TLC, total lung capacity; PaO2, arterial oxygen
tension; PaCO2, arterial carbon dioxide tension; BE, base excess; sPAP, systolic pulmonary artery pressure.
acomparison between COPD and restrictive diseases using the unpaired test or Fisher’s exact test, whatever appropriate.
bgeometric mean and SD (expressed as a factor to be multiplied with the geometric mean).
cdetermined without oxygen supplementation (n ¼ 49).
dn ¼ 28 (14 each).
S. Budweiser et al.2006r ¼ 0.42; p ¼ 0.013) assessed in the absence of oxygen
supplementation, with PaO2 (n ¼ 43; r ¼ 0.37; p ¼ 0.015)
and PaCO2 (n ¼ 43; r ¼ 0.34; p ¼ 0.026) in the presence of
oxygen supplementation, with CRP (n ¼ 43, r ¼ 0.33;
p ¼ 0.039), exacerbation (n ¼ 43; r ¼ 0.33; r ¼ 0.029) and
sPAP (n ¼ 19; r ¼ 0.50; p ¼ 0.031). When PaO2 and PaCO2
(without oxygen) and exacerbation were assessed in a
multivariate regression, only PaO2 and exacerbation re-
mained independently related to NT-proBNP (po0.05), but
not PaCO2 (p ¼ 0.094). There was no significant relationship
between NT-proBNP levels and lung function, whether
patients with obstructive or restrictive disorders were
analysed separately or not.Changes after initiation of NIV
Patients who refused NIV (n ¼ 12) were not reassessed,
while 8 patients died before re-evaluation of NT-proBNP
levels and 4 ceased NIV without readmission. Three serum
samples were lost due to a failure in storage. Thus, 33patients were observed at the follow-up visit. These
patients showed a mean (7SD) time of ventilator use of
6.173.5 h/d. A significant reduction of NT-proBNP (31.3
(0.3)%; po0.001; Fig. 2) and improvements in lung function
(FEV1, RV/TLC), blood gases (PaCO2, PaO2, base excess) and
decreases in haemoglobin levels were observed (po0.01
each; Table 2). The reduction in PaCO2 was correlated with a
decrease in NT-proBNP (n ¼ 33; r ¼ 0.43, p ¼ 0.014) while
the other parameters, which improved after therapy, were
not correlated with the changes of NT-proBNP.Prognostic value of NT-proBNP
The observation period in all patients (n ¼ 60) covered 22.5
(2.2) months. During this time, 19 patients died (all-cause
mortality 31.7%), among them 14 (73.7%) from cardio-
pulmonary causes.
In the total population (n ¼ 60), high versus low baseline
levels of NT-proBNP (using the median, 596 pg/mL) were not
significantly associated with survival (p ¼ 0.397; hazard
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Figure 2 Changes in NT-proBNP after treatment including NIV
in patients assessed at baseline and follow-up (n ¼ 33).
Figure 1 NT-proBNP levels in the total group (n ¼ 60) and the
subgroup (n ¼ 43) with chronic hypercapnic respiratory failure
(CHRF) but normal left ventricular ejection fraction and
creatinine values (n ¼ 43), compared to control subjects
(n ¼ 182).
NT-proBNP in respiratory failure 2007ratio ¼ 0.66; 95%-CI: 0.255–1.720). However, in patients
discharged without NIV, lacking adherence to NIV (ventilator
use o3 h/d) or those who ceased NIV without readmission,
elevated NT-proBNP levels were linked to poor prognosis
when using the 67th percentile of this group as cut-off value
(722 pg/mL; n ¼ 24; p ¼ 0.0091; hazard ratio ¼ 0.21; 95%-
CI: 0.022–0.580; Fig. 3), while there was only a trend when
using the median (599 pg/mL; n ¼ 24; p ¼ 0.0528; hazard
ratio ¼ 0.28; 95%-CI: 0.064–1.017).
Discussion
The current study, which is the largest to date evaluating
the role of NT-proBNP in patients with severe CHRF under-
lying different diseases, indicates that elevated NT-proBNP
levels are common in these patients, even in the absence of
HF. NT-proBNP is correlated with respiratory impairment in
terms of hypoxia, hypercapnia and exacerbation. Consis-
tently, effective treatment of the respiratory disorder,
including NIV, is associated with improved gas exchange and
markedly reduced NT-proBNP concentrations. Accordingly,
in patients without adherence to NIV, elevated NT-proBNP
was associated with impaired long-term prognosis.
NT-proBNP in cardiac and pulmonary diseases
Brain natriuretic peptides have been identified as consistent
and reliable markers of left ventricular overload or HF.1,2,15Specifically, the largest studies on acute dyspnoea have so
far suggested that dyspnoea of pulmonary origin has much
lower or even normal BNP concentrations as compared to
acute HF.4,5 In fact, only limited information is available on
the role of these peptides in severe pulmonary or respiratory
diseases.7 It seems reasonable to expect elevated BNP
peptides in these diseases, as BNP is expressed also in the
right ventricle.18 In the present study, we specifically
addressed only patients with very severe diseases where
CHRF was present and those who were admitted for
evaluation of NIV. We preferred NT-proBNP over BNP as it
probably better reflects the chronicity of the disease.6,19
Moreover, patients’ values were compared with those of a
large reference population of matched healthy subjects,
utilizing the same assay and laboratory. We thus excluded
that the application of different methods confounded our
results. In the current study, highly elevated NT-proBNP
concentrations were observed in patients with CHRF,
even after strict exclusion of patients with HF or renal
impairment.
These observations might be relevant in the differential
diagnosis of dyspnoea of patients admitted to an emergency
department. Specifically, NT-pro BNP levels of 4900 pg/mL
have been proposed as ‘‘rule-in’’ cut-point for the presence
of acute HF in patients 50–75 years old while an age-
independent cut-point of 300 pg/mL had 98% negative
predictive value to exclude acute HF.4,20 Unfortunately,
studies from emergency units mostly do not provide details
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Table 2 Changes of parameters at follow-up (n ¼ 33).
Parameter Baseline Follow-up
visit
p-
valuea
BMI (kg/m2) 29.178.9 29.378.7 1.00
NT-proBNP (pg/
mL)b
369.4
(5.0)
107.9
(3.5)
o0.001
Creatinine (mg/dL) 0.8470.19 0.8470.26 0.891
Haemoglobin (g/dL) 14.272.1 13.571.6 0.047
Leukocytes (103/
mL)
8.072.3 8.372.8 0.532
CRP (mg/dL) 8.5712.6 5.976.1 0.379
FEV1 (%pred) 35.9714.1 41.8718.8 0.001
FEV1/VC (%) 65.0723.7 64.6723.4 0.970
RV/TLC (%) 68.5710.5 63.5711.8 o0.001
pH 7.4070.03 7.4170.03 0.697
PaO2 (mmHg) 63.6712.4 65.6710.7 0.525
PaCO2 (mmHg) 57.678.0 45.775.9 o0.001
BE (mmol/L) 8.473.9 3.673.4 o0.001
pHc 7.4070.03 7.4170.03 0.587
PaO2 (mmHg)
c 52.579.2 59.7711.0 0.008
PaCO2 (mmHg)
c 53.076.4 44.774.7 o0.001
BE (mmol/L)c 8.373.9 3.172.8 o0.001
Abbreviations as in Table 1.
aaccording to the paired t-test for the comparison of
groups.
bgeometric mean and SD (expressed as a factor to be
multiplied with the geometric mean).
cdetermined without oxygen supplementation (n ¼ 26).
Figure 3 Prognostic value of NT-proBNP in the group dis-
charged without NIV, lack of adherence to NIV (ventilator use
o3 h) or patients who ceased NIV without readmission (n ¼ 24).
Significant differences in survival were seen in patients having
values either above the 67th percentile (722 pg/mL; n ¼ 16) or
below (n ¼ 8); hazard ratio ¼ 0.21; p ¼ 0.0091; 95%-CI:
0.022–0.580.
S. Budweiser et al.2008(lung function or blood gases) on the severity of pulmonary
diseases.4,20,21 Thus, it might be possible that patients with
severe respiratory diseases were underrepresented com-
pared to the present analysis.
Interestingly, a study comparing NT-proBNP levels of
patients with parenchymal lung diseases (COPD, emphyse-
ma, pulmonary fibrosis) with those of patients with primary
pulmonary hypertension found elevated levels in only 9% of
patients with parenchymal diseases.22 However, blood gas
data, which we found to be major correlates of NT-proBNP,
were not given. To our knowledge, there are only two
studies (including 11 and 28 patients) which investigated the
levels of natriuretic peptides exclusively in patients with
CHRF.12,23 Both studies reported elevated levels of BNP and
ANP, leading to the suggestion that these hormones are also
markers of right ventricular overload. Accordingly, and as
described previously,12,22,24 we found a correlation between
NT-proBNP and sPAP.
Taken together our data indicate that severe CHRF might
be associated with NT-proBNP concentrations which are
close to those found in acutely decompensated HF and
therefore should be considered as a possible differential
diagnosis in patients with dyspnoea and elevated NT-proBNP
levels.Determinants of elevated NT-proBNP levels
In chronic lung disease, hypoxia is supposed to be the most
important factor in the development of pulmonary hyper-
tension. Right ventricular wall stretch or tension, induced
by pulmonary vasoconstriction as well as direct release
from myocardium under hypoxia may be the major
mechanisms for natriuretic peptide secretion.10,25 Indeed,
after exclusion of patients with HF or renal failure, we found
PaO2 to be the most consistent predictor of elevated
NT-proBNP levels in regression analyses. Data from animal
studies and human subjects suggest, that hypercapnia
could also be involved in the development of pulmonary
hypertension.12,26
Specifically, we confirmed the association between
NT-proBNP and PaCO2, assessed prior to NIV.
12 In addition,
at the follow-up visit, an impressive reduction of NT-proBNP
had occurred which was not correlated with the improve-
ment in PaO2 but the reduction in PaCO2. However, this
correlation was weak which suggests that hypercapnia is
only one of several factors involved in the complex
mechanisms of pulmonary haemodynamics.27
We are well aware of the fact that the changes in blood
gases cannot be attributed exclusively to NIV but are
inextricably linked to concomitant medical therapy. More-
over, in some patients LTOT, which might also lead to a
decrease in BNP levels10 was installed in addition to NIV.
Nevertheless, and in line with our results, previous data
from patients with CHRF have demonstrated an improve-
ment in pulmonary haemodynamics after initiation of
NIV.11,12
In addition to blood gases, clinical signs of exacerbation
and elevated CRP were related to NT-proBNP levels, as
described recently.28 In contrast, lung function did not show
an association with NT-proBNP, similar to previous data on
BNP levels in pulmonary fibrosis.29 This seems to implicate
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NT-proBNP in respiratory failure 2009that lung function impairment per se does not result in right
ventricular overload, as long as the pulmonary vascular
system is not affected.22,27,30 Affection of this system is,
however, often observed in collagen tissue diseases in which
BNP then is predictive.8,31 Accordingly, the highest levels of
NT-proBNP were observed in patients with OHS although
their lung function impairment was small compared to that
of blood gases.
Prognostic value of NT-proBNP
Natriuretic peptides are important predictors of outcome in
cardiac diseases1,32 and pulmonary hypertension or embo-
lism.33,34 As right heart failure and pulmonary thrombosis or
embolism are frequent causes of death in severe respiratory
diseases, we additionally evaluated the relationship be-
tween NT-proBNP and prognosis. There was no significant
association in the total population, comprising patients with
and without NIV. However, in patients in whom adherence to
NIV was not demonstrated, elevated NT-proBNP were linked
to poor prognosis. Taking into account the substantial
decrease of NT-proBNP levels after initiation of NIV, the
benefits from NIV might have masked the prognostic role of
NT-proBNP in the total group.
In accordance with our data, BNP has been reported as an
independent predictor for survival in chronic respiratory
disease35 although, with some reservation, as the study
comprised only 5 end-stage deaths. Based on data from 176
patients with various chronic lung diseases, BNP has also
been identified as a marker of pulmonary hypertension and
independent prognostic parameter.8 However, the inclusion
of patients admitted for right heart catheterization in whom
pulmonary hypertension is particularly pronounced might
have led to an overestimation of the role of BNP. Most of
these patients included were hypoxemic, but hypercapnia
was not frequent, thus patients do not seem comparable to
those of our data set. Irrespective of this, these and our data
strongly support the use of natriuretic peptides in evaluating
the mortality risk in chronic lung diseases.
In conclusion, we found markedly elevated NT-proBNP
concentrations in patients with CHRF even in the absence of
left-ventricular dysfunction. This suggests that CHRF should
be considered as potential differential diagnosis in patients
with dyspnoea and elevated marker concentrations. Hypox-
emia, hypercapnia and inflammation were major factors
underlying the rise in NT-proBNP in these patients. Con-
sistently, effective treatment including NIV resulted in a
substantial decrease of NT-proBNP concentration. These
data also suggest a potential for NT-proBNP as a marker of
prognosis and treatment efficacy in patients with CHRF.
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